Introduction
Suboptimal adherence is a common burden for patients with chronic diseases, and the importance of adherence has been emphasized throughout recent studies. The World Health Or ganization states, "Increasing the effectiveness of adherence interventions may have a far greater impact on the health of the population than any improvement in specific medical treat ments" 1) . Growth hormone (GH) therapy also faces the challenge of suboptimal adherence, reaching up to 82%, and adherence in terventions are required that may help patients with a suboptimal response of GH therapy reach their growth potential 13) . Somatotropin, a recent form of recombinant human growth hormone (rhGH), is indicated in children and adolescents with growth disorders 4) . Because the majority of patients receiving GH therapy are children or adolescents, GH treatment often involves a third party (parent/guardian), and patients themselves are not motivated to take the medication In Growth Hormone (GH) therapy, suboptimal adherence is a common problem, reaching up to 82%, and there is a need for interventions to improve adherence and to maximize patients' growth potential eventually. Current studies have demonstrated the association between the rate of nonadherence and reduced height velocity. In order to maximize patients' potential to grow, an autoinjecting/ recording device, such as easypod TM , may help improve adherence and optimize the treatment effects of GH therapy. 
Abstract Graphics
lenge of needle injection becomes a big barrier for medication adherence in young patients 2, 5) . Therefore, growth hormone often comes with devices like easypod TM to help overcome the barriers to adherence. Easypod TM is an electronic autoinjector device that features preset dosing, a skin sensor, and onestep administration to im prove the convenience of patients 6, 7) . Additionally, it automatically tracks the injection schedule so patients can follow an appropri ate dose/schedule and clinicians can stay informed with data on patients' adherence to GH therapy 7) . In this review article, we will assess the general trend of adherence in GH therapy, the associa tion between nonadherence and height velocity, and the effects of easypod TM on adherence, which may lead to worse treatment outcomes eventually.
Suboptimal Adherence to GH Therapy

2)
Several studies have measured nonadherence to GH therapy using various methods and definitions ( Table 1 ). The methods for measuring adherence include issued, renewed, or encashed There is no gold standard for methods or definitions of non adherence. Therefore, depending on the measure and definition of nonadherence, studies have shown a wide range of non adherence rates, from 5 to 82%. Regardless of the various rates of nonadherence in different studies, the prevalence of suboptimal adherence is evident for patients who are undergoing GH thera py, and clinicians should confirm good adherence before making any changes to current therapy 8) .
Association Between Non-adherence and Height Velocity
Cutfield et al. observed 175 patients receiving government funded GH in New Zealand 3) . Height velocity standard deviation score (HVSDS) over 6-8 months was controlled for sex and age differences; it was significantly lower in patients with low adher ence (missed more than three doses/week) compared with pa tients with high adherence (missed less than or equal to one dose/ week) (P<0.001). HVSDS positively correlated with adherence (P<0.05) 3) . In a study in England, Kapoor et al. observed 75 pa tients using GP prescriptions data over 12 months 9) . Low adher ence was associated with reduced height velocity (HV) (P<0.005) and HVSDS. The association remained significant regardless of how long patients were receiving GH therapy 9) . Ayidin et al. 's study of 217 GHnaïve patients in Turkey also demonstrated the association between impaired growth rates and low adherence 8) .
Patients with low adherence had significantly lower HV and HVSDS compared with patients with excellent (100%) or good adherence (>=95%) (P=0.014 and P=0.015, respectively) 8) . Current studies persistently demonstrate that nonadherence to GH therapy is associated with reduced height velocity. In order to overcome the barriers of nonadherence and to maximize the patient's potential to grow, an autoinjecting device, such as easy pod TM , may help improve adherence and identify nonadherence Reported adherence -all children in patients.
Positive Effects of Easypod TM on Adherence and Health Outcome
In the study of Bozzola et al., 682 patients were observed at 206 endocrinology centers across 15 countries 6) . Adherence was defined as injection taken with less than or equal to two missed doses per month. The majority of patients (87.5%) using easypod TM were adherents over 3 months of the period ( Table   2 ). The rate of adherence was significantly higher in treatment naïve patients than in treatmentexperienced patients (89.7% vs 81.7%; P=0.0062) 6) . . According to the 2014 interim analysis, height velocity at the start of GH treatment was 4.5 cm/ year for Growth Hormonedeficient patients. After 1 year, height velocity had increased up to 7.9 cm/year with a 93.0% adherence rate with easypod TM . The correlation between adherence rate and change in height/height velocity was only weakly positive (P=0.084, 0.132). It could have been weakened by the inclusion of older children who had undergone previous GH therapy 10) . Although a direct association between height velocity and the use of easypod TM has not been established, easypod TM contrib uted to the high adherence rates of GH therapy of 87.5% and 93% in Bozzola et al. 's study and the ECOS, respectively, compared with the nonadherence rate of up to 82% in a systemic review by Fisher et al. 2, 6, 10) The positive effects of easypod TM on adher ence may result in patients reaching their growth potential and maximizing the effects of GH therapy. Additionally, patients' acceptance of easypod TM suggests easypod TM is a good treatment choice for patients for improving adherence to GH therapy 6) .
Conclusion
Suboptimal adherence to GH therapy is a common problem that results in reduced height velocity in patients with growth disorders. High adherence rates were observed in patients using easypod TM . Easypod TM is an easy/quicktouse device that had high acceptability to patients 6) . For clinicians, its automatic re cording features allow the elimination of adherence as a cause of suboptimal GH therapy response and more informed treatment decisions. Therefore, easypod TM could be considered one of the clinician's choices in helping patients with suboptimal response to GH therapy.
More than a device change should be made to improve adher ence, but easypod TM could be one of the preferred choices for improving patients' adherence and treatment outcomes. Further studies assessing different interventions for motivating patients with easypod TM and the association between the use of easypod TM and treatment outcome would be helpful in practice.
